An fda panel has endorsed the use of capivasertib in prostate cancer. However, reports indicate the panel's vote was split, suggesting some uncertainty or disagreement. The drug's status regarding breast cancer treatment is also unclear, with some reports indicating it did not receive endorsement for this use.